CC&BD pioneers research into novel drugs and biomarkers aimed at treating pediatric cancers and hematological disorders. Our multidisciplinary approach spans from laboratory breakthroughs to bedside applications. With three dedicated research laboratories focusing on sarcomas, neural tumors, and rare anemias, we cover diverse areas of study. Our clinical research initiatives encompass a Personalized medicine program, a clinical trials unit, and investigations into hematopoietic stem cell transplantation (HSCT) and cellular/gene therapies.
Our team has achieved recognition through prestigious human resources programs (ISCIII, Rio Hortega, Sara Borrell and PhD-VHIR fellowships). Additionally, we are about to open the ‘first-in-child’ clinical trial utilizing ABTL0812 for neuroblastoma treatment. Furthermore, in 2023, our group secured multiple national (TACTIC) and international collaborative projects such as MONALISA, demonstrating our commitment to advancing research and innovation.
eCORE
- Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation
- Cancer
- Personalized Medicine, Innovative Diagnostics, Molecular Imaging & Digital Health
- Woman & Child Health & Rare Diseases
Team
Group Leader
Lucas Moreno Martín-Retortillo
Principal Investigator (PI)
M Mar Mañu, Josep Roma, Miguel F Segura, Aroa Soriano, Cristina Diaz de Heredia
Researchers
María J Pérez García, Ariadna Boloix, Khloud Elsharawy, Patricia Zarzosa, Anna Llort, Anna Collado, Raquel Hladun, Lorena Valero, Pablo Velasco, Constantino Sábado, Luis Gros, Thais Murciano, Paula Pérez, Laura Murillo, Blanca Espinosa, Angela Menarguez, María Pérez-Torres Lobato, Marina Ortiz, Laura Alonso, Maria Isabel Benítez, Luz Uria, Gabriela Guillen, Melissa Panesso, Marina Bonfill, Anna Salo, Maria Oliveras
PhD Students
Amira Idrizovic, Valeria Rizzuto, Guillem Pons, Julia Sansa, Lia García, Adrià Molero Valenzuela, Marta Miera
Lab Technicians
Paula Cabré
Nursing and Technical Staff
Laura Romero, Sergio Manresa, Andrea Vilaplana, Carolina A Torres Barbosa, María de los Ángeles Rodriguez, Claire Diout, Elena Andetta, Carlota Aguilera, Raquel Andreu, Raquel Anta
Publications
Moreno L, DuBois SG, Glade Bender J, Mauguen A, Bird N, Buenger V, Casanova M, Doz F, Fox E, Gore L, Hawkins DS, Izraeli S, Jones DTW, Kearns PR, Molenaar JJ, Nysom K, Pfister S, Reaman G, Smith M, Weigel B, Vassal G, Zwaan CM, Paoletti X, Iasonos A, Pearson DDJ
Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents
J Clin Oncol. Jun 20;41(18):3408-3422.
DOI: 10.1200/JCO.22.02430
IF: 45.4
Moreno L, Teira P, Croop JM, Gerber NU, André N, Aerts I, Gros Subias L, De Wilde B, Bautista F, Turpin B, Kunduri S, Hamidi A, Lawrence T, Streby KA
A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors
Front Pediatr. 2023 May 24;11:1183295
DOI: 10.3389/fped.2023.1183295.
IF: 2.6
Pons G, Gallo-Oller G, Navarro N, Zarzosa P, Sansa-Girona J, García-Gilabert L, Magdaleno A, Segura MF, Sánchez de Toledo J, Gallego S, Moreno L, Roma J.
Analysis of Cancer Genomic Amplifications Identifies Druggable Collateral Dependencies within the Amplicon
Cancers (Basel) 2023. Mar 7;15(6):1636.
DOI: 10.3390/cancers15061636.
IF: 5.2
Mañú Pereira MDM, Colombatti R, Alvarez F, Bartolucci P, Bento C, Brunetta AL, Cela E, Christou S, Collado A, de Montalembert M, Dedeken L, Fenaux P, Galacteros F, Glenthøj A, Gutiérrez Valle V, Kattamis A, Kunz J, Lobitz S, McMahon C, Pellegrini M, Reidel S, Russo G, Santos Freire M, van Beers E, Kountouris P, Gulbis B.
Sickle cell disease landscape and challenges in the EU: the ERN-EuroBloodNet perspective.
Lancet Haematol. 2023 Aug;10(8):e687-e694.
DOI: 10.1016/S2352-3026(23)00182-5.
IF: 24.7
Galán V, Beléndez C, Echecopar C, Estival P, Sissini L, Olivas R, Bueno D, Molina B, Fuentes C, Regueiro A, Benítez I, Plaza M, Margarit A, Rifón J, Pascual A, Palomo P, Urtasun A, Fuster JL, Díaz de Heredia C, Fernández Navarro JM, González-Vicent M, Ruz B, Pérez-Martínez A.
Treosulfan-Based Conditioning Regimen In Pediatric Hematopoietic Stem Cell Transplantation: A Retrospective Analysis on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
Transplant Cell Ther. 2023 Nov;29(11):702.e1-702.e11.
DOI: 10.1016/j.jtct.2023.08.016.
IF: 3.2
Projects
MONALISA: A SIOPEN pragmatic clinical trial to MOnitor NeuroblastomA relapse with LIquid biopsy Sensitive Analysis.
Principal Investigator: Lucas Moreno
Agency: European commission
Funding: 84,800 €
Period: 2023-2027
GENOMED4ALL – Genomics and Personalized Medicine for all though Artificial Intelligence in Haematological Diseases
Principal Investigator: M Mar Mañu
Agency: European Comission
Funding: 434,000 €
Period: 2021-2024
A phase I trial of ABTL0812 in paediatric patients with advanced cancer enriched for neuroblastoma patients
Principal Investigator: Lucas Moreno
Agency: Ministerio de Ciencia e Innovación
Funding: 826,760 €
Period: 2022-2025
TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas
Principal Investigator: Lucas Moreno
Agency: Ministerio de Ciencia e Innovación
Funding: 343,600 €
Period: 2022-2025
Implementation and new biomarker development for Personalised Medicine for Childhood Cancers in Spain
Principal Investigator: Lucas Moreno
Agency: Instituto de Salud Carlos III.
Funding: 369,260€
Period: 2022-2025
Patents
Compounds for use in preventing or treating cancer
Priority Number: PCT/EP2019/067557
Priority Date: 29/06/2018
Applicants: VHIR/LEITAT/SELABTEC
Peptides for the treatment of cancer and/or metastasis.
Priority Number: EP19383084.1
Priority Date: 05/12/2019
Applicants: VHIR/BCN peptides
Nanovesicles and its use for nucleic acid delivery.
Priority Number: PCT/EP2020/063195
Priority Date: 12/05/2020
Applicants: VHIR / CSIC / CIBER
A pharmaceutical combination for the treatment of cancer
Priority Number: WO2018EP62554
Priority Date: 09/08/2017
Applicants: Ability Pharmaceuticals S.L
